Functional
Foods as catalysts of the nutrition evolution into nutrigenomics: a
scholastic example of a fermented papaya preparation (Immun-Âge)
1,2,3F.
Marotta, 2E. Minelli, 3P. Marandola
1Hepato-Gastroenterology
Dept. S. Giuseppe Hospital, Milano; 2WHO-Cntr for Biotechnology
& Traditional Medicine, University of Milano, Italy; 3Urology
Dept. University of Pavia and G.A.I.A. antiaging Foundation,
Functional
Food: a recent history dating back in time
"Functional Foods" represent an emerging opportunity and the
development of innovative solutions aimed at acting on organic systems
as well as on more general topics relating to consumer health. This
is different to previous situations, when mainly retrospective epidemiological
studies or empirical experiences were carried out on single nutrients.
Such a new and growing interest by the scientific community follows
research deeply oriented to clinics and supplemented by an accurate
study on nutrients, genomics and single nutritional requirement diagnostics.
Already in 1993, Nature published a report that Japan is exploring roles
between food and medicine. Clearly the success of "Functional Foods"
depends also on the food industry's capacity to develop new effective
products which on the one side meet consumers' needs and on the other
must have positive effects on health, supported and validated by scientific
research and therefore far beyond a simplistic claim of positive properties,
as recently outlined in a meeting, organised by a non profit, non governmental
international association.
Definition
and demanded features
This approach has lead, in the past few years, to constant changes in
the Functional Food definition which an authoritative scientific European
panel defined as follows, in 1999 " A nutrient can only be easily
considered functional if it was satisfactorily proved that it can positively
change one or more target functions, besides nutritional effects, as
to consistently improve health, and well-being while reducing any affection
risk. A Functional Food should ideally be a nutrient and should not
change its efficacy when entering into a diet; it should not be either
a pill or a capsule". It was then agreed that, from a practical
view point, a Functional Food should comply with the following features:
1) a natural food;
2) a food which was simply supplemented by a component;
3) a food which was no longer holding a component;
4) a food which the nature of one of more components had been changed;
5) a food which one or more component availability had been changed;
6) a combination of the previous features.
It was then outlined how, besides its nutritional properties or physiological
effects, it is mandatory to offer a consistent safety profile of its
administration. Such a condition is nothing but a prerequisite to further
develop any Functional Food. From the recommendations of such a European
commission, it is possible to come to the conclusion that "The
design and development of a Functional Food is a key factor, besides
a scientific challenge, which should be mainly based on consistent scientific
knowledge in terms of target functions and their possible modulations
by nutritional components". It is furthermore stressed that "Functional
Foods are not universal, therefore a nutritional-specific approach would
be no longer suitable, but rather a basic scientific approach would
only apply".
It
is important to outline a new concept within nutrition, on the role
played by Functional Foods science, which must be followed to get useful
clinical interventions (tab.
1).
An ancient Chinese proverb says that "medicine and food are isogenic"
and it is not by chance that in 1984, in Japan, a unique national study
group was set up, sponsored by the Ministry of Education, Science and
Culture (MESC), aiming at exploring the interface between nutrition
and science. Scientists in time studied and defined a series of foods
and nutrients which were officially listed in the category "foods
to be specifically administered for health-care", stressing and
recognising their nutritional value, after undergoing a consistent bio-fermentation
process. Such a classification is still a legally-binding tool against
media communication of wrongly defined natural products, misleading
or simply recalling data from the literature but not followed by specific
validations of the product itself.
Synergies, markers and development strategy of nutrigenomics
A biochemistry and molecular biology specific development together with
biotechnological methods were conducted to support the hypothesis that
some nutrients could modulate body functions, playing a role in general
good health as well as in the reduction of disease risk. depending on
life style. Such assessments had to be in line with consistent identification
markers, both directly connected (functional factors) to the process
to be modified, as well as indirectly associated (indicators). In fact
from the human genome project conclusion, a post-genomic study has started,
which should mainly be correlated with Functional Foods, availing itself
of sophisticated technologies such as DNA tip technology and others,
which lead to nutrigenomics. Such a word was only recently introduced
and represents a leap forward in comparison with observational studies
which were mainly based on research in the bioactive nutritional component
field. Nutrigenomics mainly aims at studying genetic and epigenetic
interactions with a nutrient as to lead to a phenotype change and therefore
to the cell metabolism, differentiation or apoptosis. Furthermore, to
stress the scientific research importance, the simple fact that research
is effectively carried out on the nutrient which apparently is "functionally"
effective, requires that to the minimum effective quantity leading to
the above-mentioned changes is defined. There are in fact many pre-clinical
studies which use a bioactive nutritional component at concentrations
which can not be practically administered. More recent papers suggest
that cells are able to adapt themselves when exposed to excessive quantities
of nutrients. As previously stated, it would be highly incoherent, if
not with no scientific application, to enforce any approach to a natural
product:
1)
which is only nutrient-specific;
2)
and moreso, if generally referring to properties simply retrieved from
literature, but with no specific validation or bioavailability study.
What is more, a series a far-sighted companies and food industries are
consistently sponsoring independent validation studies on natural products,
even when not imposed by the regulation in force;
3)
taking into account the negative effect of the variable efficacy of
the nutrient according to the different formulation (lyophilised products,
dehydration processes at low or high temperature, extracts, etc.) or
associations. Isoflavons and soy proteins stand out among all, where
the role of each single component is not clear yet, as well as the effects
of any possible association or the best formulation of soy itself.
As
for new generation studies, however, it is too early yet and still many
are the interactions to be assessed between nutrients and host and between
nutrients themselves, and possibly many mechanisms will play an important
role all together. Biological modifications in the presence of a Functional
Food would briefly be anti-oxidant (followed by a series of possible
genic sequences mediated by an increased transcriptional rate by: cytochrome
P450s, glutatione-S-transpherase, NAD(p)H: kinone-reductase, UDP-glucuronosyltranspherase,
microsomial hydrolysis, aphta-toxin B1-aldehyde reductase, dihydrodiol-dehydrogenase,
aldehyde-dehydrogenase, glutatione-reductase, etc.), supporting the
detoxigenic enzymes, carcinogen build-up and metabolism block, hormonal
homeostasis change, delaying the cell division or inducing apoptosis.
Immun-Âge
history: it is an example of the rational and evidence-based biotechnological
study.
That being stated, it is far more interesting to further and briefly
analyse the study and development process, still in progress of Immun-Âge,
a specific product derived from the technologically advanced and controlled
bio-fermentation process of Carica Papaya Linn, in the absence of genetic
manipulation, within a Japanese research institute carried out in compliance
with every quality control and environmental-friendly validated standards.
After a series of initial reports, a couple of decades ago, by Japanese
scientists on a series of populations living in the Philippines and
eating a lot of papaya fruit, 15 years ago, a research institute was
set up devoted to the study of "functional" properties of
a series of specific compounds within such a diet. The most attention
was paid to Carica Papaya Linn, which collected in the Philippines,
was further processed in Japan, with other exotic fruits through a long
fermentation process according to natural methods.
Basic
research: a compulsory process to follow in the development of biotechnologies
From the extraction of the final product, a series of experimental scientific
activities and studies were carried out by the Neuroscience Department,
Molecular Biology Institute at the Okayama University in Japan, directed
by Prof. Mori. Such studies, carried out with sophisticated methods
among which was Electron Spin Resonance, highlighted that such a product
consisting of fermented Papaya exhibited a powerful anti-oxidizing activity
on in vitro cerebral cells as well on the in vivo epilepsy experimental
model, where the epileptogenic monoamine neutral release was consistently
reduced. Prof. Mori' s group also proved the capacity of fermented papaya
to reduce the increase of free radical concentration as well as superoxide
dismutase at the brain level in elderly rats followed by the reduction
of experimental ischemia/reperfusion-induced cerebral damage. It was
furthermore highlighted to be consistent in vitro anti-oxidizing product
capacities even when tested for one hour at high temperatures (100°C)
and acidic pH (1,2). What is more, such features were confirmed
after a long-term storage.
Then, after thoroughly refining the product and getting its certifications
by the governmental body (table
2), two important studies were carried out with international
institutes to further assess the product, such as its possible effects
on the immune system, together with the Kyoto Pasteur Institute, as
well as its effects on the oxidizing stress in co-operation with the
Molecular Biology Department at the UCLA in Berkley directed by Prof.
Packer, a widely recognised authority on the subject, leading to a more
detailed assessment of its activity mechanism. Such successful studies,
still in progress, led to a series of extremely interesting in vitro
and ex vivo evidence data. The group from the Pasteur Institute in Kyoto,
starting from the evidence of a positive effects of Immun-Âge
on the Natural Killer population on an experimental sarcoma model, proved
its capacity on human beings to affect the interferon-g production.
Such data was further proven by studies supporting the positive activity
of Immun-Âge on the macrophage function isolated from rats and
human beings. In the same time period, the working group co-ordinated
by Prof. Mori showed the consistent protecting effect by Immun-Âge
on oxidizing stress on isolated rat hearts. These data may have potential
clinical implications when considering that severe injury such as ischemia/reperfusion
is a unique epiphenomenon present during myocardial infarction and in
stroke. Such data were then confirmed in oxidative damage of other tissues
such as kidney, liver and brain. The same group also shed some light
on the causal connection of the immune-modulating activity of Immun-Âge
with its anti-oxidising features. In fact on a rat macrophage line,
important experimental evidence was put forward on how Immun-Âge
can upregulate nitric acid production induced by interferon-g. Immun-Âge
would then exhibit a nutrigenomic effect able to affect the messenger
RNA expression both of inducible nitric acid and of TNF-a and of interleukin
1ß.
Such an activity was further assessed when two different fractions were
arbitrarily separated, according to their different molecular weight
(cut off: MW 3.000), both confirming the previous results as well as
the new important evidence of their action on the NF-kB binding to DNA
as a clear explanation of the transcriptional increase of inducible
nitric oxide gene. The two different fractions however proved a series
of differences in terms of macrophage stimulation and anti-oxidising
scavenging activity. It is therefore possible to prove, for example,
that a different immune-modulating activity could depend on the different
(1-3)-ß-D-glucan concentration, which represents the
most representing portion of some peculiar yeasts, used in the Immun-Âge
bio-fermentation process.
Clinical
evidence supported by research: a long-awaited evolution from empirism
Support offered by scientific evidence and a series of works on human
beings represented the foundations to plan a series of clinical studies.
In 1995 a oncolo- haematological Russian study group proved, on young
subjects undergoing radiotherapy against severe mielo- and lympho-leukaemia,
how the administration of this specific fermented papaya preparation,
as proved in the previous experimental studies by Prof. Mori, managed
to significantly reduce clinical side-effects (encephalopathy score:
anorexia, nausea, vomiting, convulsions, dizziness) and bio-humoral
abnormalities (change of the redox status due to the erythrocyte gluthatione
depletion and leukocyte SOD increase, deficit of the mononuclear cell
activity). During the same time period a group of Italian, French and
Japanese scientists co-ordinated a series of studies on the alcoholic
liver diseases which proved how Immun-Âge allows reduction of
alcoholic oxidative stress (reduction of plasma and erythrocyte level
of malonyldialdehyde as well as of plasma lipoperoxides) during the
initial phases of withdrawal, when it is possible to mark a persistence
of the microsomial system activation leading to the ethanol oxidation,
with a consequent continuance of the pro-oxidative state and during
chronic alcoholic abuse. More precisely, taking into account the low
compliance in the case of withdrawal, it was proved how the administration
of Immun-Âge to alcoholics led to the following effects:
1.
a significant improvement of haemorheology (reduction of the whole blood
viscosity, recovery of the erythrocyte deformability and increase of
blood filtration capacity through specific membrane). Such a consistent
increase of the malonylaldehyde concentration in the erythrocytes in
the case of chronic alcoholics leads, through lipoperoxidising effects,
to a lipid
asymmetry destabilisation.
Such data proved also to be interesting for an Israeli working group
on thalassaemia which got preliminary in vitro data about the protective
effects of Immun-Âge on erythrocytes collected from subjects suffering
from b-thalassaemia
2.
a significant recovery of the latent malabsorption of vitamin B12 due
to the interference of alcohol-induced oxidising effects on the gastric
mucosa as the binding site level between intrinsic factor and cyanocobalamin.
Such
evidence on the efficacy of Immun-Âge on oxidising stress inducted
by alcohol on the gastric mucosa was also based on the concomitant evidence
of the significant protective effect (macro- and micro-scopic and biochemical
as well) on healthy subjects, after being administered a test-dose of
ethanol (40 ml 80% ethanol).
According
to the previous results on the antigenotoxic effect and on the DNA in
vitro protection by Immun-Âge from the group of Prof. Mori and
more recently of Prof. Packer who highlighted its iron chelating effect,
a new clinical trial was carried out on gastric precancerous lesions.
A group of Italian and Japanese scientists proved in a controlled and
randomised study carried out for a six month period on patients suffering
from atrophic chronic gastritis without the presence of Helycobacter
pilori that both a generic anti-oxidant mixture, high dosage vitamin
E and Immun-Âge reduced of a series of mucosa markers relating
to oxidative stress. However, Immun-Âge alone managed to significantly
reduce the two markers used as an expression of a precancerous biochemical
change, that is ornithine decarboxylase and mainly 8-oxoguanine which
is one of the most frequently used biochemical markers relating to DNA
oxidative damage.
At
the time of the first clinical trials by the Kyoto Pasteur group on
the immuno-modulating Immun-Âge effects and relating observation
reports (increase of the CD8+ and QOL score), on the positive beneficial
effect which HIV-affected patients could benefit from, a series of studies
were started by Prof. M. Weksler of the Cornell University in the USA
and Prof. L. Montagnier, former director of the virology laboratory
of the Pasteur Institute in Paris and present chairman of the World
AIDS Research and Prevention Foundation. In a preliminary study, which
is going to be further enlarged, it was proved that the Immun-Âge
administration for 3 weeks before anti-flu vaccination in 10 hospitalised
elderly patients consistently improved their specific antibody response
in comparison with a control group which was only administered the vaccine.
What is more, Prof. Montagnier's group carried out a study on the administration
of Immun-Âge to HIV-positive patients and data from the open preliminary
research proves how such a product, when associated to an anti-retroviral
treatment, can significantly improve the CD4+ concentration as well
as hemoglobineamia, weight increase and cenaesthesia.
Finally,
at present in Great Britain studies are being carried out on Immun-Âge
on experimental Parkinson models while in a highly qualified French
laboratory a series of studies are being enforced on the possible fraction
separations inside the product to better assess its specific features.
It
goes without saying that it is highly important to move to a diet rich
in vegetable foods which, if correctly enforced, offers the availability
of micro-nutrients and anti-oxidants which are more than enough to comply
with the body requirement in the case of normal health conditions and
in the absence of important psychical and physical burdens. What simply
depended on common sense, was underlined long ago by an authoritative
international no-profit institute which stressed how a healthy diet
should not be replaced by a non-controlled diet rich in supplements
or food-like compounds as vitamins, extracts or lyophilised products,
mainly when the variability of such products in each single batch is
uncontrolled or even worse, when no certified titration was carried
out. However the absence of specific and referenced studies on each
single nutraceutical attempt can not be counterbalanced by general data
collected from literature. However legislation and standards are still
open about fortified foods supplemented by specific nutrients which
deserve a discussion on its own. As previously underlined by Prof. Packer
during an international congress we are in front of a consistent evolution
of anti-oxidants implying the study on how some of them from a simple
scavenger function are instead able to interact in a complex way with
the redox balance and immune-modulating network through a genic adjustment.
Immun-Âge
certainly represents a Functional Food highly complying with the new
features of the new nutrigenomic product category
References
| 1) |
Nature 1993; 364:180. |
| 2) |
"Functional
Foods - Scientific and Global Perspectives", Intl. Life Science
Institute symposium, Paris, France 2001. |
| 3) |
European Commission's Concerted Action on Functional Food Science
in Europe- FUFOSE, 1999. |
| 4) |
EU Novel Food Regulation, European Commission 1997. |
| 5) |
Roberfroid MB et al. Br J Nutrition 2002; 88 :133-138. |
| 6) |
Food for Specified Health Use, FOSHU. |
| 7) |
Ventre JC et al. Science 2001. |
| 8) |
DellaPenna D. Science 1999. |
| 9) |
Milner JS. Moving beyond observational studies, in Functional foods
and Health: a US perspective. Br J Nutrition 2002. |
| 10) |
Jackson AA, Adv Exp Med Biol 2000 e Fafournoux P et al. Biochem
J 2000. |
| 11) |
Kneale C et al. Survey on health claims, University of Sydney, Nutrition
Res. Found.,1997. |
| 12) |
Crouse JR et al. Arch Intern Med 1999. |
| 13) |
Santiago LA et al. Free Rad Biol Med 1991; 11:379-383 |
| 14) |
Santiago LA et al. Med Sci Res 1992 ; 21 :139-141. |
| 15) |
Santiago LA et al. Oxygen Radicals 1992 ; 405-408. |
| 16) |
Santiago LA et al. Neurochem Res 1993; 18:717-717. |
| 17) |
Mori A et al. NeuroReport 1993; 4:1031-1034. |
| 18) |
Osato JA et al. Med Sci Res 1992; 20:27-28. |
| 19) |
Okuda H et al. Clinical Rep. 1993; 27:4249-4258. |
| 20) |
Kishida et al. Neurosciences 1994; 20:149-152 |
| 21) |
Kishida et al.J Interferon res 1994; 14:179. |
| 22) |
Shinohara M et al. Canad J Physiol Pharmacol 1994; 72:1 |
| 23) |
Osato JA et al. Phys Chem Biol Med 1995; 2:87-95. |
| 24) |
Osato JA et al. Nutrition 1995; 11:568-572. |
| 25) |
Haramaki N, Packer L et al. Biochem Mol Biol Int 1995; 36:1263-1269. |
| 26) |
Marcocci L et al. Biochem Mol Biol Int 1996; 38:535-541. |
| 27) |
Kobuchi H et al. Biochem Mol Biol Int 1997; 43:141-152. |
| 28) |
Rimbach G et al. Life Sci 2000; 67:679-694. |
| 29) |
Korkina LG et al Nutrition 1995; 11:555-558. |
| 30) |
Marotta F et al. HepatoGastroenterol. 1997; 44:1360-1366. |
| 31) |
Marotta F et al.. Hepato-Gastroenterology 2001; 48: 511-17. |
| 32) |
Prof. Rachmilewitz, ORI Report, UNESCO, Paris, France, 2002. |
| 33) |
Marotta F, Hepato-Gastroenterology 2000; 47: 1189-94. |
| 34) |
Marotta F et al. Digestion 1999; 60: 538-43. |
| 35) |
deCastro-Bernas G et al. Med Sci Res 1993; 21:107-108. |
| 36) |
Rimbach G et al. Anticancer Res 2000; 20:2907-2914. |
| 37) |
Marotta F et al. Annals of N Y Acad Sci, 2004. |
| 38) |
Mimaya J. Life Living Guidance-Ministry of Health, Japan, 1998. |
| 39) |
Weksler M. Personal communication, The Press Club, Paris 2002. |
| 40) |
Chenal H, Montagnier L. Personal communication at From Genomics
to Nature, University of Tor Vergata, Rome, 2003. |
| 41) |
"Antioxidant:
Scientific Basis, Regulatory Aspects and Industry Perspectives",
Antioxidant Task Force-Intl. Life Science Institute symposium, Bruxelles,
1996. |
| 42) |
Ghosh S et al. Commercial Validity of Claims for Biological Activity
and Regulatory Issues, Clinical Science; 2003 104:547-556. |
| 43) |
Howe PCR What makes a Functional Food functional? -substantiating
health claims. Asia-Pacific J Clin Nutrition 2000; 9:108-112. |
| 44) |
International Symposium on Free Radicals and Health: Molecular Intervention
and Protection of Lifestyle-Related Disease, 23-25 Ottobre 2003,
Sakata, Japan. |
Table
2
Fermented
Papaya Preparation (100 gr)
FPP/100g Composition. (Japan Food Res.Lab, Tokyo)
| Carbohydrates
|
90.7
g |
Arginine
|
16
mg |
| Moist |
8.9 g |
Lysine
|
6 mg |
| Proteins |
0.3
g |
Hystidine
|
5
mg |
| Fats
|
absent
|
Phenylalanine
|
11
mg |
| Ashes |
0.1 g |
Tyrosine
|
9
mg |
| Fibres |
Absent |
Leucine |
18
mg |
| Vitamin
B6 |
17
mcg |
Isoleucine |
9
mg |
| Pholic
acid |
2
mcg |
Methionine |
5 mg |
| Niacin |
240
mcg |
Valine |
13
mg |
| Calcium |
2.5
mg |
Glycine
|
11mg |
| Potassium |
16.9 mg |
Proline |
8
mg |
| Magnesium
|
4.6
mg |
Gluthamic
acid |
37
mg |
| Copper
|
14
mcg |
Serine |
11
mg |
| Zinc
|
75
mcg |
Treonine |
8
mg |
| |
|
Aspartic
acid |
27
mg |
| |
|
Triptophane
|
2
mg |
back
to text